Under the Freedom of Information Act one can retrieve some of the DOD filings of progress under CTSO Award W81XWH-22-C-0046.
In a recent April 2024 filing statement by Dr. Maryann Gruda she stated:
"Greater availablilty of universal plasma products wil significantly simplfy logistics and reduce costs for both military and civilian transfusion services. Phase II SBIR studies perfomred at WRNMMC showed the BGA-Absorber prototype removed anti-A-titer and anti-B titers by 99% from high titer human plasma, without affecting coagulation factors. Building on these exciting results, our proposed efforts are directed towards combining BGA reduction with spray or freeze-drying efforts to generate universal dried plasma that is suitable and readily available under austere conditions".
The May filing actually shows how the product packaging would work.
In many ways this opporunity seems much lager, more profitable and sooner benefit to shareholders than current FDA approvals underway.
Why is Dr. Chan not talking about this?
Maybe to some investors looking at the new Jefferies $20 million raise?
Looking forward to additional filings.
Maybe a major medical device company like Boston Scientfic or Medtronic could swoop in, buy CTSO under an unfriedly tender for $60-80 milion, fire the Board and all the overhead people, keep the new manufacturing facility and use their own global distribution to quickly build a $200-500 million annual business (with 75% plus gross margins) selling to every naval ship, cruise ship, amubulance, EMS, police and fire fleet?
Market Data 
Markets 
AI
